Phase 2 Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to follow the treatment plan, attend scheduled visits, complete required tests, and sign a consent form agreeing to take part
- People who are 18 years of age or older at the time of signing the consent form
- People whose general physical functioning is rated at 0 or 1 on a standard oncology performance scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site)
- People whose expected survival is at least 12 weeks
- People who have at least one tumour that can be measured using standard imaging criteria
- Women of childbearing potential who are willing to use highly effective contraception from the time of signing the consent form until 6 months after the last dose of the trial drug, and who have a negative pregnancy test within 7 days before the first dose
- Male participants who are willing to use highly effective contraception from the time of signing the consent form until 6 months after the last dose, and who agree not to donate sperm during that period
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have used immune-modifying medications within 2 weeks before the first dose of the trial drug
- People who have received a live vaccine within 4 weeks before the first dose, or who are expected to need a live vaccine during treatment or within 4 weeks after the last dose
- People with uncontrolled fluid build-up around the lungs, abdomen, or heart
- People who have had an active infection within 2 weeks before the first dose of the trial drug
- People with an ongoing infectious disease
- Women who are pregnant, breastfeeding, or planning to become pregnant
- People with active hepatitis B or active hepatitis C
- People with a history of mental illness that interferes with understanding or consenting to the study, or a history of drug abuse, alcoholism, or drug addiction
- People whom the trial investigator considers to have other conditions that may affect their ability to follow the study requirements or that make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: yongmei Yin, The First Affiliated Hospital with Nanjing Medical University
Phone: 025-83718836
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR); Occurrence of adverse event (AE) and serious adverse event (SAE); Progression-free Survival(PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.